R. Herbst, J. Heymach, and S. Lippman, Lung Cancer, New England Journal of Medicine, vol.359, issue.13, pp.1367-1380, 2008.
DOI : 10.1056/NEJMra0802714

. Yoshizawaa, . Motoin, . Rielygj, . Simacs, . Geraldwl et al., Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases, Modern Pathology, vol.57, issue.5, pp.653-664, 2011.
DOI : 10.1038/modpathol.2010.232

L. Coate, T. John, M. Tsao, and F. Shepherd, Molecular predictive and prognostic markers in non-small-cell lung cancer, The Lancet Oncology, vol.10, issue.10, pp.1001-1010, 2009.
DOI : 10.1016/S1470-2045(09)70155-X

R. Sordella, D. Bell, D. Haber, and J. Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways, Science, vol.305, issue.5687, pp.1163-1167, 2004.
DOI : 10.1126/science.1101637

T. Lynch, D. Bell, R. Sordella, S. Gurubhagavatula, R. Okimoto et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004.
DOI : 10.1056/NEJMoa040938

J. Subramanian and R. Govindan, Lung Cancer in Never Smokers: A Review, Journal of Clinical Oncology, vol.25, issue.5, pp.561-570, 2007.
DOI : 10.1200/JCO.2006.06.8015

T. Mitsudomi and Y. Yatabe, Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer, Cancer Science, vol.2, issue.12, pp.1817-1824, 2007.
DOI : 10.1038/nm0607-675

Y. Yatabe and T. Mitsudomi, Epidermal growth factor receptor mutations in lung cancers, Pathology International, vol.62, issue.2, pp.233-244, 2007.
DOI : 10.1038/nrc1947

M. Arcila, K. Nafa, J. Chaft, N. Rekhtman, C. Lau et al., EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics, Molecular Cancer Therapeutics, vol.12, issue.2, pp.220-229, 2013.
DOI : 10.1158/1535-7163.MCT-12-0620

D. Jackman, B. Yeap, L. Sequist, N. Lindeman, A. Holmes et al., Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib, Clinical Cancer Research, vol.12, issue.13, pp.3908-3914, 2006.
DOI : 10.1158/1078-0432.CCR-06-0462

J. Wu, C. Yu, Y. Chang, C. Yang, J. Shih et al., Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.17, issue.11, pp.3812-3821, 2011.
DOI : 10.1158/1078-0432.CCR-10-3408

M. Fukuoka, Y. Wu, S. Thongprasert, P. Sunpaweravong, S. Leong et al., Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non???Small-Cell Lung Cancer in Asia (IPASS), Journal of Clinical Oncology, vol.29, issue.21, pp.2866-2874, 2011.
DOI : 10.1200/JCO.2010.33.4235

S. Jiang, K. Yamashita, M. Yamamoto, C. Piao, A. Umezawa et al., EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance, International Journal of Cancer, vol.17, issue.11, pp.2480-2486, 2008.
DOI : 10.1002/ijc.23868

A. Sakurada, H. Lara-guerra, N. Liu, F. Shepherd, and M. Tsao, Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.3, issue.5, pp.527-529, 2008.
DOI : 10.1097/JTO.0b013e318168be93

K. Taniguchi, J. Okami, K. Kodama, M. Higashiyama, and K. Kato, Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib, Cancer Science, vol.98, issue.5, pp.929-935, 2008.
DOI : 10.1093/carcin/bgi044

J. Jakobsen and J. Sorensen, Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, vol.3, issue.1, pp.289-299, 2012.
DOI : 10.1007/s00280-011-1791-9

Y. Yatabe, K. Matsuo, and T. Mitsudomi, Mutations Is Extremely Rare in Lung Adenocarcinoma, Journal of Clinical Oncology, vol.29, issue.22, pp.2972-2977, 2011.
DOI : 10.1200/JCO.2010.33.3906

J. Mattsson, J. Imgenberg-kreuz, K. Edlund, J. Botling, and P. Micke, Consistent mutation status within histologically heterogeneous lung cancer lesions, Histopathology, vol.2021, issue.4, pp.744-751, 2011.
DOI : 10.1111/j.1365-2559.2012.04245.x

G. Oxnard, M. Arcila, C. Sima, G. Riely, J. Chmielecki et al., Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clinical Cancer Research, vol.17, issue.6, pp.1616-1622, 2011.
DOI : 10.1158/1078-0432.CCR-10-2692

R. Rosell, M. Molina, C. Costa, S. Simonetti, A. Gimenez-capitan et al., Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations, Clinical Cancer Research, vol.17, issue.5, pp.1160-1168, 2011.
DOI : 10.1158/1078-0432.CCR-10-2158

E. Calvo and J. Baselga, Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, Journal of Clinical Oncology, vol.24, issue.14, pp.2158-2163, 2006.
DOI : 10.1200/JCO.2006.06.5961

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, The Lancet Oncology, vol.12, issue.2, pp.175-180, 2011.
DOI : 10.1016/S1470-2045(10)70087-5

W. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger et al., International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, Journal of Thoracic Oncology, vol.6, issue.2, pp.244-285, 2011.
DOI : 10.1097/JTO.0b013e318206a221
URL : https://hal.archives-ouvertes.fr/inserm-00561753

A. Didelot, L. Corre, D. Luscan, A. Cazes, A. Pallier et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples, Experimental and Molecular Pathology, vol.92, issue.3, pp.275-280, 2012.
DOI : 10.1016/j.yexmp.2012.03.001

K. Pallier, A. Houllier, L. Corre, D. Cazes, A. Laurent-puig et al., No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer, Molecular Carcinogenesis, vol.419, issue.7, pp.581-585, 2009.
DOI : 10.1002/mc.20538

K. Livak and T. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, pp.402-408, 2001.

L. Sequist, R. Martins, D. Spigel, S. Grunberg, A. Spira et al., Mutations, Journal of Clinical Oncology, vol.26, issue.15, pp.2442-2449, 2008.
DOI : 10.1200/JCO.2007.14.8494

M. Santarpia, D. Pas, T. Altavilla, G. Spaggiari, L. Rosell et al., Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients, Future Oncology, vol.9, issue.3, pp.327-345, 2013.
DOI : 10.2217/fon.13.6

K. Kobayashi and K. Hagiwara, Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC), Targeted Oncology, vol.361, issue.10, pp.27-33, 2013.
DOI : 10.1007/s11523-013-0258-9

Z. Chen, W. Zhong, X. Zhang, J. Su, X. Yang et al., EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas, The Oncologist, vol.17, issue.7, pp.978-985, 2012.
DOI : 10.1634/theoncologist.2011-0385

Y. Honda, N. Takigawa, S. Fushimi, N. Ochi, T. Kubo et al., Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors, Lung Cancer, vol.78, issue.1, pp.121-124, 2012.
DOI : 10.1016/j.lungcan.2012.07.003

K. Shimizu, T. Yukawa, Y. Hirami, R. Okita, S. Saisho et al., Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer, Targeted Oncology, vol.9, issue.4, pp.237-242, 2012.
DOI : 10.1007/s11523-012-0241-x

K. Schmid, N. Oehl, F. Wrba, R. Pirker, C. Pirker et al., EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases, Clinical Cancer Research, vol.15, issue.14, pp.4554-4560, 2009.
DOI : 10.1158/1078-0432.CCR-09-0089

C. Gow, Y. Chang, Y. Hsu, M. Tsai, C. Wu et al., Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer, Annals of Oncology, vol.20, issue.4, pp.696-702, 2009.
DOI : 10.1093/annonc/mdn679

A. Kalikaki, A. Koutsopoulos, M. Trypaki, J. Souglakos, E. Stathopoulos et al., Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC, British Journal of Cancer, vol.1, issue.6, pp.923-929, 2008.
DOI : 10.1111/j.1349-7006.2004.tb02203.x

H. Bai, Z. Wang, Y. Wang, M. Zhuo, Q. Zhou et al., Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer, PLoS ONE, vol.99, issue.5, p.54170, 2013.
DOI : 10.1371/journal.pone.0054170.t001

L. Sun, Q. Zhang, H. Luan, Z. Zhan, C. Wang et al., Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice, Journal of Experimental & Clinical Cancer Research, vol.30, issue.1, p.30, 2011.
DOI : 10.1002/cncr.23925

K. Goto, M. Satouchi, G. Ishii, K. Nishio, K. Hagiwara et al., An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting, Annals of Oncology, vol.23, issue.11
DOI : 10.1093/annonc/mds121

C. Ma, S. Wei, and Y. Song, T790M and acquired resistance of EGFR TKI: a literature review of clinical reports, J Thorac Dis, vol.3, pp.10-18, 2011.

G. Ellison, G. Zhu, A. Moulis, S. Dearden, G. Speake et al., mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples, Journal of Clinical Pathology, vol.66, issue.2, pp.79-89, 2012.
DOI : 10.1136/jclinpath-2012-201194

B. Wei, K. Yang, J. Zhao, Y. Chang, Z. Ma et al., Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer, Journal of Experimental & Clinical Cancer Research, vol.33, issue.1, p.5, 2014.
DOI : 10.1371/journal.pone.0070839

Y. Chang, C. Wu, J. Shih, and Y. Lee, Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers, Annals of Surgical Oncology, vol.9, issue.2, pp.543-50, 2011.
DOI : 10.1245/s10434-010-1295-6

S. Matsumoto, K. Takahashi, R. Iwakawa, Y. Matsuno, Y. Nakanishi et al., FrequentEGFR mutations in brain metastases of lung adenocarcinoma, International Journal of Cancer, vol.6, issue.6, pp.1491-1495, 2006.
DOI : 10.1002/ijc.21940

M. Akbari, M. Hansen, J. Halgunset, F. Skorpen, and H. Krokan, Low Copy Number DNA Template Can Render Polymerase Chain Reaction Error Prone in a Sequence-Dependent Manner, The Journal of Molecular Diagnostics, vol.7, issue.1, pp.36-39, 2005.
DOI : 10.1016/S1525-1578(10)60006-2

T. Grob, T. Hoenig, T. Clauditz, D. Atanackovic, A. Koenig et al., Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer, Lung Cancer, vol.79, issue.3, pp.221-227, 2012.
DOI : 10.1016/j.lungcan.2012.11.009

. Lupo, Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?, Journal of Translational Medicine, vol.12, issue.1, p.131, 2014.
DOI : 10.1016/S1525-1578(10)60006-2
URL : https://hal.archives-ouvertes.fr/inserm-00998916